---
title: "Kelun-Biotech returns to profit with FY26 H1 net income RMB 388.01 million; revenue rises 2.9% to RMB 978.34 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296096012.md"
description: "Sichuan Kelun-Biotech returned to profitability in FY26 H1, posting a net income attributable to shareholders of RMB 388.01 million, compared to a loss the previous year. Revenue increased 2.9% to RMB 978.34 million, with operating profit turning positive at RMB 250.03 million. Commercial product sales more than doubled to RMB 657.04 million. However, R&D expenses rose 25.7% to RMB 768.43 million, and selling costs more than doubled. Other net income reached RMB 752.06 million, largely due to settlement income."
datetime: "2026-08-17T11:10:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296096012.md)
  - [en](https://longbridge.com/en/news/296096012.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296096012.md)
generator: "portal-rs"
---

# Kelun-Biotech returns to profit with FY26 H1 net income RMB 388.01 million; revenue rises 2.9% to RMB 978.34 million

-   Sichuan Kelun-Biotech posted a profit attributable to shareholders of RMB 388.01 million, returning to profit from a loss a year earlier. \* Revenue rose 2.9% to RMB 978.34 million, while operating profit turned positive at RMB 250.03 million. \* R&D expenses increased 25.7% to RMB 768.43 million, while selling and distribution costs more than doubled to RMB 390.6 million. \* Other net income climbed to RMB 752.06 million, driven by RMB 702.72 million of settlement income. \* Commercial product sales more than doubled to RMB 657.04 million; cash and financial assets increased 4.9% to RMB 4.78 billion. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260817-12287215), on August 17, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [002422.CN](https://longbridge.com/en/quote/002422.CN.md)
- [06990.HK](https://longbridge.com/en/quote/06990.HK.md)

## Related News & Research

- [Kelun-Biotech: Buy Rating Reaffirmed as Strong sac-TMT Momentum Drives Target Price Increase from HK$507.11 to HK$642.29](https://longbridge.com/en/news/296393818.md)
- [11:06 ETPeptide Synthesis Market: USD 2.59 Billion by 2031, Driven by Therapeutic Demand & Advanced Synthesis Technologies, Says Mordor Intelligence](https://longbridge.com/en/news/296247020.md)
- [Lytix Biopharma names Timothy Herpin chief business officer](https://longbridge.com/en/news/296197559.md)
- [CARsgen FY26 H1 net loss narrows to RMB 70.84 million; revenue rises 21.49% to RMB 61.92 million](https://longbridge.com/en/news/296243257.md)
- [JDC: Record growth in turnover and EBITDA, with strong outlook driven by new regulation and AI](https://longbridge.com/en/news/296247395.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**